person · Reporting owner

CARPENTER WILLIAM F III

Disclosed activity across 2 companies

Tapewire entity: 26646
SEC CIK: 0001189136

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
FB Financial CorpFBK · Entity 4279	Director	July 31, 2026	August 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FB Financial Corp

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,981	Reported balance After 2026-07-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 270 · Balance 28,981 F1: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LEGACY LIFEPOINT HEALTH, INC.

Report date November 16, 2018 · Filed November 20, 2018

Section 16 reporting ended · disclosed 2018-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
CommonSEC Table I · non-derivative	Direct	Ending reported balance After 2018-11-16 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2018-11-09 · Gift · Disposed 10,000 · Balance 475,422 Row 2 · 2018-11-13 · Gift · Disposed 36,198 · Balance 439,224 Row 3 · 2018-11-14 · Gift · Disposed 261,539 · Balance 177,685 Row 4 · 2018-11-16 · Disposition to issuer · Disposed 177,685 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest.
CommonSEC Table I · non-derivative	IndirectBy Retirement Plan	Reported balance After 2018-11-16 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2018-11-16 · Disposition to issuer · Disposed 1,629 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.34 · Expires 2023-02-19	Direct	Reported balance After 2018-11-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2022-02-21	Direct	Reported balance After 2018-11-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-11-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.51 · Expires 2020-02-23	Direct	Reported balance After 2018-11-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-11-16 · Disposition to issuer · Disposed 235,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.88 · Expires 2021-02-23	Direct	Reported balance After 2018-11-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-11-16 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.22 · Expires 2026-02-23	Direct	Reported balance After 2018-11-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-11-16 · Disposition to issuer · Disposed 242,932 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2019-02-24	Direct	Reported balance After 2018-11-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-11-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.00 · Expires 2025-02-24	Direct	Reported balance After 2018-11-16 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-11-16 · Disposition to issuer · Disposed 255,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.90 · Expires 2024-02-25	Direct	Reported balance After 2018-11-16 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-11-16 · Disposition to issuer · Disposed 195,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.85 · Expires 2028-02-27	Direct	Reported balance After 2018-11-16 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2018-11-16 · Disposition to issuer · Disposed 239,167 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.50 · Expires 2027-02-28	Direct	Reported balance After 2018-11-16 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2018-11-16 · Disposition to issuer · Disposed 245,482 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2018-11-16 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2018-11-16 · Disposition to issuer · Disposed 198,555 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-12-31	Direct	Reported balance After 2018-11-16 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2018-11-16 · Disposition to issuer · Disposed 81,009 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest.

F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.

F3: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 09, 2018 Filed Nov 20, 2018 21:49 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	GiftCommon	10,000	$0.00	$0.00	Disclosure SEC source: 0001225208-18-015767 · doc4.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,422 Read SEC document
February 28, 2018 Filed Mar 1, 2018 17:55 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Tax withholdingCommon	25,288	$46.10	$1,165,776.80	Disclosure SEC source: 0001225208-18-004985 · doc4.xml · nonDerivative · entry 2 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,300 F1 · shares: Pursuant to the terms of the Company's 2013 Long-Term Incentive Plan, these shares were automatically withheld for payment of the tax liability incident to the vesting of a restricted stock award. Read SEC document
February 28, 2018 Filed Mar 2, 2018 10:47 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	PurchaseCommon	21,368	$46.80	$999,983.94	Disclosure SEC source: 0001225208-18-005051 · doc4.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,668 F1 · price: The price shown is the weighted average price for multiple transactions within a price range of $46.625 to $47.00 per share. Upon request, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:55 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionRestricted Stock Units · Derivative	64,400	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001225208-18-004985 · doc4.xml · derivative · entry 6 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,555 Underlying: Common · 64,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Vesting of these performance-based RSUs was contingent upon the Issuer's three-year annualized total shareholder return or TSR as of December 31, 2017 relative to the S&P GICS Sub-industry: Health Care Facilities with over $500 million in revenues, or its equivalent. F4 · derivative.expiration_date: Vesting of these performance-based RSUs was contingent upon the Issuer's three-year annualized total shareholder return or TSR as of December 31, 2017 relative to the S&P GICS Sub-industry: Health Care Facilities with over $500 million in revenues, or its equivalent. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:55 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	GrantRestricted Stock Units · Derivative	118,388	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001225208-18-004985 · doc4.xml · derivative · entry 5 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,955 Underlying: Common · 118,388 shares Expires not disclosed F3 · derivative.exercise_date: The Performance Period with respect to these restricted stock units ("RSUs") is January 1, 2018 through December 31, 2020. Each RSU represents the right to receive, upon vesting, up to two shares of the Issuer's common stock. Vesting of these performance-based RSUs is contingent upon the achievement of annually established performance targets for diluted earnings per share for each of the three fiscal years of the Performance Period, with the final number of shares of common stock issued under the RSUs subject to modification based on the Issuer's three-year annualized total shareholder return as of December 31, 2020 relative to the S&P GICS Sub-Industry Health Care Facilities with over $500 million in revenues, or its equivalent. Any RSUs earned during the Performance Period will be paid out 75% in 2020 and 25% in 2021, contingent upon continued employment with the Issuer. F3 · derivative.expiration_date: The Performance Period with respect to these restricted stock units ("RSUs") is January 1, 2018 through December 31, 2020. Each RSU represents the right to receive, upon vesting, up to two shares of the Issuer's common stock. Vesting of these performance-based RSUs is contingent upon the achievement of annually established performance targets for diluted earnings per share for each of the three fiscal years of the Performance Period, with the final number of shares of common stock issued under the RSUs subject to modification based on the Issuer's three-year annualized total shareholder return as of December 31, 2020 relative to the S&P GICS Sub-Industry Health Care Facilities with over $500 million in revenues, or its equivalent. Any RSUs earned during the Performance Period will be paid out 75% in 2020 and 25% in 2021, contingent upon continued employment with the Issuer. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:55 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	GrantNon-Qualified Stock Options (Right to buy) · Derivative	239,167	$0.00 Strike: $44.85	$0.00	Disclosure SEC source: 0001225208-18-004985 · doc4.xml · derivative · entry 4 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,167 Underlying: Common · 239,167 shares Expires 2028-02-27 F2 · derivative.exercise_date: The options vest in four equal installments beginning on the first anniversary of the date of grant. Read SEC document
February 27, 2018 Filed Mar 1, 2018 17:55 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionCommon	64,400	$0.00	$0.00	Disclosure SEC source: 0001225208-18-004985 · doc4.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 17, 2017 Filed Jul 19, 2017 18:30 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionNon-Qualified Stock Options (Right to buy) · Derivative	17,653	$0.00 Strike: $25.79	$0.00	Disclosure SEC source: 0001225208-17-012748 · doc4.xml · derivative · entry 4 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 17,653 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person. Read SEC document
July 17, 2017 Filed Jul 19, 2017 18:30 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	SaleCommon	17,653	$65.06	$1,148,583.62	Disclosure SEC source: 0001225208-17-012748 · doc4.xml · nonDerivative · entry 2 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,188 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person. F3 · price: The price shown is the weighted average price for multiple transactions within a price range of $64.80 to $65.60 per share. Upon request, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Read SEC document
July 17, 2017 Filed Jul 19, 2017 18:30 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionCommon	17,653	$25.79	$455,270.87	Disclosure SEC source: 0001225208-17-012748 · doc4.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of options set to expire in February 2018. Read SEC document
June 15, 2017 Filed Jun 19, 2017 18:16 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionNon-Qualified Stock Options (Right to buy) · Derivative	82,347	$0.00 Strike: $25.79	$0.00	Disclosure SEC source: 0001225208-17-011497 · doc4.xml · derivative · entry 4 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,653 Underlying: Common · 82,347 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2017 Filed Jun 19, 2017 18:16 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	SaleCommon	82,347	$64.15	$5,282,881.20	Disclosure SEC source: 0001225208-17-011497 · doc4.xml · nonDerivative · entry 2 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,188 F2 · price: The price shown is the weighted average price for multiple transactions within a price range of $64.00 to $64.75 per share. Upon request, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Read SEC document
June 15, 2017 Filed Jun 19, 2017 18:16 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionCommon	82,347	$25.79	$2,123,729.13	Disclosure SEC source: 0001225208-17-011497 · doc4.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of options due to expire in February 2018. Read SEC document
March 01, 2017 Filed Mar 2, 2017 18:46 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Tax withholdingCommon	25,670	$64.30	$1,650,581.00	Disclosure SEC source: 0001225208-17-005419 · doc4.xml · nonDerivative · entry 2 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,188 F1 · shares: Pursuant to the terms of the Company's 2013 Long-Term Incentive Plan, these shares were automatically withheld for payment of the tax liability incident to the vesting of a restricted stock award. Read SEC document
February 28, 2017 Filed Mar 2, 2017 18:46 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	GrantRestricted Stock Units · Derivative	81,009	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001225208-17-005419 · doc4.xml · derivative · entry 6 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,009 Underlying: Common · 81,009 shares Expires 2019-12-31 F4 · derivative.exercise_date: The Performance Period with respect to these restricted stock units (RSUs) is January 1, 2017 through December 31, 2019. Each RSU represents the right to receive, upon vesting, up to two shares of the Issuer's common stock. Vesting of these performance-based RSUs is contingent on criteria such as (i) the Issuer's cumulative EBITDA during the Performance Period; (ii) the Issuer's diluted earnings per share during the Performance Period; and (iii) the Issuer's three-year annualized total shareholder return as of December 31, 2019 relative to the S&P GICS Sub-Industry: Health Care Facilities with over $500 million in revenues, or its equivalent. F4 · derivative.expiration_date: The Performance Period with respect to these restricted stock units (RSUs) is January 1, 2017 through December 31, 2019. Each RSU represents the right to receive, upon vesting, up to two shares of the Issuer's common stock. Vesting of these performance-based RSUs is contingent on criteria such as (i) the Issuer's cumulative EBITDA during the Performance Period; (ii) the Issuer's diluted earnings per share during the Performance Period; and (iii) the Issuer's three-year annualized total shareholder return as of December 31, 2019 relative to the S&P GICS Sub-Industry: Health Care Facilities with over $500 million in revenues, or its equivalent. Read SEC document
February 28, 2017 Filed Mar 2, 2017 18:46 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionRestricted Stock Units · Derivative	61,200	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001225208-17-005419 · doc4.xml · derivative · entry 5 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,967 Underlying: Common · 61,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Vesting of these Restricted Stock Units was conditioned upon the Issuer's three-year annualized total shareholder return as of December 31, 2016 relative to the S&P GICS Sub-industry: Health Care Facilities with over $500 million in revenues. F3 · derivative.expiration_date: Vesting of these Restricted Stock Units was conditioned upon the Issuer's three-year annualized total shareholder return as of December 31, 2016 relative to the S&P GICS Sub-industry: Health Care Facilities with over $500 million in revenues. Read SEC document
February 28, 2017 Filed Mar 2, 2017 18:46 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	GrantNon-Qualified Stock Options (Right to buy) · Derivative	245,482	$0.00 Strike: $64.50	$0.00	Disclosure SEC source: 0001225208-17-005419 · doc4.xml · derivative · entry 4 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,482 Underlying: Common · 245,482 shares Expires 2027-02-28 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning on the first anniversary of the date of grant. Read SEC document
February 28, 2017 Filed Mar 2, 2017 18:46 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	Exercise / conversionCommon	61,200	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005419 · doc4.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 29, 2016 Filed Feb 10, 2017 17:06 UTC	LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283	GiftCommon	5,100	$57.75	$294,525.00	Disclosure SEC source: 0001225208-17-002787 · doc5.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,658 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.